Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2022

View Archived Issues

2-Benzyllawsone shown to protect mice against polymicrobial sepsis

1st Bio Therapeutics identifies new ABL/LRRK2/LRRK2 mutant/RIPK2 inhibitors

Council of Scientific and Industrial Research patents nigericin derivatives

New psilocin prodrugs discovered at Compass Pathfinder

Novel antibacterials synthesized at the University of Jordan

Cybin IRL describes new 5-HT2 receptor agonists

LCFA-CoA inhibits NME1 and regulates cancer metastasis

TSC2 blockade activates mTORC1, improves photoreceptor survival and delays vision loss in RP

NuclixBio and PharmAbcine enter collaborative research agreement

Catamaran expands research collaboration with University of Minnesota on CAR-NK cell engineering

NexImmune enters melanoma research and evaluation collaboration with NYU Langone center

NSF grant supports Iaso's vaccine delivery research targeting infectious diseases and cancer

Gadeta advances GDT-201 toward IND filing for colorectal cancer

SIWA-318H shows efficacy in immune-competent humanized mouse xenograft model for pancreatic cancer

Mer inhibition as a promising new therapeutic strategy against septic ALI/ARDS

Activating activators is strategy against apoptosis defectors

FDA approves IND application for SM-17 for asthma

Elektrofi and Immunoprecise collaborate on self-administered formulation of PolyTope TATX-03

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...